Literature DB >> 8651279

Mucopolysaccharidosis IVA: four new exonic mutations in patients with N-acetylgalactosamine-6-sulfate sulfatase deficiency.

S Tomatsu1, S Fukuda, A Yamagishi, A Cooper, J F Wraith, T Hori, Z Kato, N Yamada, K Isogai, K Sukegawa, N Kondo, Y Suzuki, N Shimozawa, T Orii.   

Abstract

We report four new mutations in Japanese patients with mucopolysaccharidosis IVA (MPSIVA) who were heterozygous for a common double gene deletion. A nonsense mutation of CAG to TAG at codon 148 in exon 4 was identified, resulting in a change of Q to a stop codon and three missense mutations. V (GTC) to A (GCC) at codon 138 in exon 4, P (CCC) to S (TCC) at codon 151 in exon 5, and P (CCC) to L (CTC) at codon 151 in exon 5. Introduction of these mutations into the normal GALNS cDNA and transient expression in cultured fibroblasts resulted in a significant decrease in the enzyme activity. V138A and Q148X mutations result in changes of restriction site, which were analyzed by restriction-enzyme assay. P151S and P151L mutations that did not alter the restriction site were detected by direct sequencing or allele specific oligohybridization. Detection of the double gene deletion was initially done using Southern blots and was confirmed by PCR. Haplotypes were determined using seven polymorphisms to the GALNS locus in families with the double gene deletion. Haplotype analysis showed that the common double gene deletion occurred on a single haplotype, except for some variation in a VNTR-like polymorphism. This finding is consistent with a common founder for all individuals with this mutation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651279      PMCID: PMC1914620     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  36 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Heterogeneity of Morquio disease.

Authors:  M Beck; J Glössl; A Grubisic; J Spranger
Journal:  Clin Genet       Date:  1986-04       Impact factor: 4.438

3.  cDNA cloning, nucleotide sequence and expression of the gene for arylsulfatase in the sea urchin (Hemicentrotus pulcherrimus) embryo.

Authors:  H Sasaki; K Yamada; K Akasaka; H Kawasaki; K Suzuki; A Saito; M Sato; H Shimada
Journal:  Eur J Biochem       Date:  1988-10-15

4.  Thrombosis and oestrogens.

Authors:  M F Oliver
Journal:  Lancet       Date:  1967-09-02       Impact factor: 79.321

5.  The enzymic defect in Morquio's disease: the specificity of N-acetylhexosamine sulfatases.

Authors:  A L Horwitz; A Dorfman
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

6.  Human glucosamine-6-sulfatase cDNA reveals homology with steroid sulfatase.

Authors:  D A Robertson; C Freeman; P V Nelson; C P Morris; J J Hopwood
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

7.  Residual activity in fibroblasts from two brothers with the late-onset form of N-acetylgalactosamine-6-sulphate sulphatase deficiency.

Authors:  K Sukegawa; T Orii
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

8.  A sensitive procedure for the diagnosis of N-acetyl-galactosamine-6-sulfate sulfatase deficiency in classical Morquio's disease.

Authors:  J Glössl; H Kresse
Journal:  Clin Chim Acta       Date:  1978-08-15       Impact factor: 3.786

9.  Deficiencies of glucosamine-6-sulfate or galactosamine-6-sulfate sulfatases are responsible for different mucopolysaccharidoses.

Authors:  N Di Ferrante; L C Ginsberg; P V Donnelly; D T Di Ferrante; C T Caskey
Journal:  Science       Date:  1978-01-06       Impact factor: 47.728

10.  Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3.

Authors:  M Matsumura; W J Becktel; B W Matthews
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

View more
  6 in total

Review 1.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

2.  Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  A M Montaño; K Sukegawa; Z Kato; R Carrozzo; P Di Natale; E Christensen; K O Orii; T Orii; N Kondo; S Tomatsu
Journal:  J Inherit Metab Dis       Date:  2007-09-17       Impact factor: 4.982

3.  Mucopolysaccharidosis IVA: characterization of a common mutation found in Finnish patients with attenuated phenotype.

Authors:  Adriana Maria Montaño; Ilkka Kaitila; Kazuko Sukegawa; Shunji Tomatsu; Zenichiro Kato; Haruki Nakamura; Seiji Fukuda; Tadao Orii; Naomi Kondo
Journal:  Hum Genet       Date:  2003-04-30       Impact factor: 4.132

4.  Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.

Authors:  Vũ Chí Dũng; Shunji Tomatsu; Adriana M Montaño; Gary Gottesman; Michael B Bober; William Mackenzie; Miho Maeda; Grant A Mitchell; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-26       Impact factor: 4.797

5.  Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.

Authors:  A Morrone; K L Tylee; M Al-Sayed; A C Brusius-Facchin; A Caciotti; H J Church; M J Coll; K Davidson; M J Fietz; L Gort; M Hegde; F Kubaski; L Lacerda; F Laranjeira; S Leistner-Segal; S Mooney; S Pajares; L Pollard; I Ribeiro; R Y Wang; N Miller
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

Review 6.  Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.

Authors:  Kazuki Sawamoto; José Víctor Álvarez González; Matthew Piechnik; Francisco J Otero; Maria L Couce; Yasuyuki Suzuki; Shunji Tomatsu
Journal:  Int J Mol Sci       Date:  2020-02-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.